Treatment of Severe Hypertension in Children with Renal Disease

  • Alan B. Gruskin
  • H. Jorge Baluarte
  • Martin S. Polinsky
  • Bruce A. Kaiser
  • Sharon A. Perlman
  • Bruce Z. Morgenstern
Part of the Developments in Nephrology book series (DINE, volume 7)


Severe hypertension and hypertensive emergencies in children most often occur in association with secondary forms of high blood pressure and may develop in children with previously unrecognized disease or as a sudden change in children with known hypertension. The term hypertensive crisis or hypertensive emergency is used to denote a clinical situation in which the blood pressure has been elevated for some period of time and ought to be lowered over minutes, or hours depending on the patient’s clinical status. The clinical presentation of hypertensive emergencies varies. Life threatening hypertensive symptoms, such as acute heart failure, pulmonary edema or neurologic changes require immediate lowering of the blood pressure. (Table I)


Antihypertensive Agent Severe Hypertension Renin Angiotensin System Major Side Effect Renin Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pascual, A.V.: Hypertensive Crises: Diagnosis and Strategies in Treatment, Hospital Medicine, January 1981, pp 43 – 59.Google Scholar
  2. 2.
    Byron, F.B: The pathogenesis of hypertensive encephalopathy and its relation to the malignant phase of hypertension-experimental evidence from the hypertensive rat. Lancet 2: 201, 1954.CrossRefGoogle Scholar
  3. 3.
    Reinmuth, O.M., Beteta. E., and Scheinberg, P.: Total cerebral blood flew in cerebral vascular disease in relation to hypertension. Neurology 16: 815, 1966.Google Scholar
  4. 4.
    Strandgaard, S., MacKenzie, E.T., Sengupta, D., et al.:Upper limits of autoregulation of cerebral blood flew in the baboon. Circ. Res. 34: 435, 1974.Google Scholar
  5. 5.
    Cuneo, R.A., and Caronna, J.J.: The neurologic complications of hypertension. Med. Clin. North Am. 61: 565, 1977.Google Scholar
  6. 6.
    Calhoun, J.: Ocular manifestations in disorders of the blood, blood vessels, heart, and lungs, and in the histiocytosis syndrome. In: Harley, R.D. (ed) Pediatric Ophthalmology. W.B. Saunders, 1975, p 656.Google Scholar
  7. 7.
    Kincaid-Smith, P.: Malignant Hypertension, Cardiovascular Reviews & Reports, Is 41, 1980.Google Scholar
  8. 8.
    Leuman, E.P.: Blood pressure and hypertension in childhood and adolescence. In: Frick, H. von P., von Harnack, G.A., Martini, G.A., Prader, A., Schoen, R. and Wolff, H.P. (eds): Advances in Internal Medicine and Pediatrics. Bd 43 Springer-Verlag 1979, p 111.Google Scholar
  9. 9.
    Volhard, F., Fahr, K.T.: Die Brightsche Nierenkranheit. Springer-Verlag, 1914.Google Scholar
  10. 10.
    Keith, N.M., Wagener, H.P., Parker, N.W.: Seme different types of essential hypertension: Their course and prognosis. Am. J. Med. Sci. 197: 332, 1939.CrossRefGoogle Scholar
  11. 11.
    Kincaid-Smith, P., McMichael, J., Murphy, E.A.: The clinical course and pathology of hypertension with papilledema (malignant hypertension). J. Med. 105 (new series 27): 117, 1958.Google Scholar
  12. 12.
    Keith, T.A. III: Hypertension Crisis - Recognition and Management. JAMA, 237: 1570, 1977.PubMedCrossRefGoogle Scholar
  13. 13.
    Report of the Task Force on Blood Pressure Control in Children; Prepared by the National Heart, Lung, and Blood Institute’s Task Force on Blood Pressure Control in Children. Pediatrics, 59: 797, 1977.Google Scholar
  14. 14.
    Guidelines for the Evaluation and Management of the Hypertensive Patient: U.S. Department of Health, Education, and Welfare, U.S. Public Health Service, National Institutes of Health, DHEW Publication no. (NIH) 74–593, Sept. 1, 1973.Google Scholar
  15. 15.
    Laragh, J.H.: Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am. J. Med. 55: 261, 1973.PubMedCrossRefGoogle Scholar
  16. 16.
    Hiner, L.B., and Gruskin, A.B.: The physiology of blood pressure regulating normal and abnormal. Pediatr. Ann. 6: 373, 1977.Google Scholar
  17. 17.
    Moser, M.: Management of Hypertensive Emergencies. Drug Therapy, May 1974, pp 143 - 157.Google Scholar
  18. 18.
    Bailie, M. D., Mattiolo, L. F.: Hypertension: Relationships between pathophysiology and therapy, J.Pediatr. 95: 789, 1980.Google Scholar
  19. 19.
    Naranjo, G., Scmani, P., and Elberg, A.J: The challenge of a pediatric hypertensive crisis- Drug Therapy, April 1979, pp 130 – 141.Google Scholar
  20. 20.
    McLain, L.G.: Therapy of Acute Severe Hypertension in Children, JAMA, 239: 755, 1978.PubMedCrossRefGoogle Scholar
  21. 21.
    Ranee, C.P., Aibus, G.S., Balfe, J.W., Kooh, S.W.: Persistent Systemic Hypertension in Infants and Children, Pediatr. Clin.North Amer. 21: 801, 1974.Google Scholar
  22. 22.
    Perry, H.M.: The Management of Malignant Hypertension. Drug Therapy, October 1971, pp 33 – 43.Google Scholar
  23. 23.
    Finnerty, F.A.: Hypertensive Crisis. JAMA 229: 1479, 1974.PubMedCrossRefGoogle Scholar
  24. 24.
    AMA Committee on Hypertension: The Treatment of Malignant Hypertension and Hypertensive Emergencies. JAMA, 228: 1673, 1974.CrossRefGoogle Scholar
  25. 25.
    Mendlcwitz, M.: Management of Hypertensive Emergencies. Hospital Medicine, December 1979, pp 63 – 67.Google Scholar
  26. 26.
    Reisman, L. and Selden, R.V: Management of Systemic Hypertension in Children. Pediatr. Ann. 11: 604, 1982.Google Scholar
  27. 27.
    Loggie, J.M.H.: Hypertension in Children and Adolescents. J. Pediatr. 74? 640, 1969.Google Scholar
  28. 28.
    Powell, H.R., Rotenberg, E., Williams, A.L., et al.: Plasma renin activity in acute poststreptococcal glomerulonephritis and the haemolytic-uremic syndrcrne. Arch. Dis. Child. 49: 802, 1974.Google Scholar
  29. 29.
    Repetto, H.A., Lewy, J.E., Brando, J.L., et al.: The renal functional response to furosemide in children with acute glomerulonephritis. J. Pediatr. 80: 660, 1972.Google Scholar
  30. 30.
    Gordillo-Paniagua, G., Velasquez-Jones, L., Martini, R., et al.: Sodium nitroprusside treatment for severe arterial hypertension in children. J. Pediatr. 87: 799, 1975.PubMedCrossRefGoogle Scholar
  31. 31.
    Etteldorf, J.N., Smith, J.D., and Johnson, C.: The effect of reserpine and its combination with hydralazine on blood pressure and renal hemodynamics during the hypertensive phase of acute nephritis in children. J. Pediat. 48: 129, 1956.PubMedCrossRefGoogle Scholar
  32. 32.
    Lowenthal, D.T, Pennock, R., Likoff, W. and Onesti, G: Therapy of Hypertension in the Dialysis Patient, in Flanagement of the Cardiac Patient v/ith Renal Failure. SA Davis Co., 1981, P 155.Google Scholar
  33. 33.
    Vidt, D.G.: The Management of Hypertension in Renal Failure. The Kidney 9: 15, 1976.Google Scholar
  34. 34.
    Garrett, B.N.: Treatment of Hypertension in Patients with Chronic Renal Failure. Contemporary Dialysis, pp 21–33, April, 1981.Google Scholar
  35. 35.
    Onesti, G., Swartz, C., Remirez, R. and Brest, A.N.: Bilateral nephrectomy for control of hypertension in uremia. Trans. Amer. Soc. Artif. Intern. Organs 14: 361, 1969.Google Scholar
  36. 36.
    Vertes, V., Cangiano, J.L., Berman, L.B., Gould, A.: Hypertension in end-stage renal disease. Netf Eng. J. Med. 280: 978, 1969.Google Scholar
  37. 37.
    Weidmann, P., Maxwell, M.H., Lupu, A.N., Lanin, A.J., and Massry, S.G.: Plasma renin activity and blood pressure in terminal renal failure. Net-7 Eng. J. Med. 285: 757, 1971.Google Scholar
  38. 38.
    Gruntzig, A., Vetter, W., Meier, E.: Treatment of Renovascular Hypertension v/ith Percutaneous Transluminal Dilation of a Renal Artery Stenosis. Lancet. 1: 801, 1978.PubMedCrossRefGoogle Scholar
  39. 39.
    Vaughan, E.D., Jr., Sos, T.A., Sniderraan, K.W., Pickering, T.G., Case, D.B., Sealey, J.H., Laragh, J.H.: Renal Venous Renin Secretory Patterns Before and After Percultaneous Transluminal Angioplasty. In: Laragh, J.H., Buhler, F.R., Seldin, D.W. (eds). Frontiers in Hypertension Research. New York: Springer-Ver lag, lybl, p 173.Google Scholar
  40. 40.
    Vaughan, E.D., Jr., Buhler, F.R., Laragh, J.H., Sealey, J.E., Baer, L., Bard, R.H.: Renovascular Hypertension: Renin Measurements to Indicate Hypersecretion and Contralateral Suppression, Estimate Renal Plasira Flow and Score for Surgical Curability. Am. J. Med., 55: 402, 1973.PubMedCrossRefGoogle Scholar
  41. 41.
    Ehrlich, R.M.: Vesicoureteral Reflux: A surgeon’s perspective. Pediatr. CI. N.Airer. 28: 827, 1982.Google Scholar
  42. 42.
    Koch-Weser, J., Hydralazine: N.Engl.J.Med. 295: 320, 1976.CrossRefGoogle Scholar
  43. 43.
    Freis, E.D., Rose J.C., Higgins, T.F., et al: The hemodynamic effects of hypotensive drugs in man. IV. 1-hydrazinophthalazine. Circulation 0: 199, 1953.Google Scholar
  44. 44.
    Perry, H.M., Jr: Late toxicity to hydralazine resembling systemc lupus erythematosus or rheumatoid arthritis. Am. J.Med. 54: 58, 1973.PubMedCrossRefGoogle Scholar
  45. 45.
    Sinaiko, A.R., Mirkin, B.L.: Clinical pharmacology of antihypertensive drugs in children. Pediatr.Clin.North.Am. 25 (1): 146, 1978.Google Scholar
  46. 46.
    VanZwierten, P.A.: The central action of antihypertensive drugs mediated via central alpha receptors. J.Pham.Pharmacol. 25: 89, 1973.Google Scholar
  47. 47.
    Mohaimied, S. et al. -.Effect of methyldopa on plasma renin activity in man. Cir.Res. 25: 543, 1969.Google Scholar
  48. 48.
    Furhoff, A: Adverse reactions with methyldopa. Acta Med.Scand. 203: 425, 1978.PubMedCrossRefGoogle Scholar
  49. 49.
    Koch-Weser, J.: Diazoxide. N.Engl. J jyied. 294: 1271, 1976.Google Scholar
  50. 50.
    Powell, W.J. Jr., Green, R.M., Whiting R.B., et al.:Action of diazoxide on skeletal muscle vascular resistance. Circ.Res. 28: 167, 1971.PubMedGoogle Scholar
  51. 51.
    Johnson, B.F.: Diazoxide and renal function in man. Clin.Pharmacol.Ther. 12: 815, 1971.PubMedGoogle Scholar
  52. 52.
    Boerth, R.C. and Long, W.R.: Dose-Response Relation of Diazoxide in Children with Hypertension. Circulation, 56, 1062, 1977.PubMedGoogle Scholar
  53. 53.
    Ogilvie, R.I., Nadeau, J.H., Sitar, D.S.: Diazoxide Concentration-Response Relation in Hypertension. Hypertension 4: 167, 1982.PubMedGoogle Scholar
  54. 54.
    O’Malley, K., Vesasco M.,Pruitt, A., et al.: Decreased plasma protein binding of diazoxide in uremia. Clin. Pharmacol. Ther. 18: 53, 1975.PubMedGoogle Scholar
  55. 55.
    Sellers, E.M., Koch-Weser, J: Displacement of warfarin frcm human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin. Pharmacol. Ther. 11: 524, 1970.PubMedGoogle Scholar
  56. 56.
    Finnerty, F.A.,Jr., Davidov, M., Mroczek, W.J., Gavillovich, L.: Influence of extracellular fluid volume on response to antihypertensive drugs. Clin. Res. 27 (suppl 1): 71, 1970.Google Scholar
  57. 57.
    Charles, M.A., Danforth E. Jr: Nonketoacidotic hyperglycemia and coma during intravenous diazoxide therapy in uremia. Diabetes 20: 501, 1971.PubMedGoogle Scholar
  58. 58.
    Palmer, R.F., and Lasseter, K.C.: Sodium nitroprusside. N. Engl. J. Med. 292: 294, 1975.PubMedCrossRefGoogle Scholar
  59. 59.
    Cohn, J.N.: Blood pressure and cardiac performance. Am.J.Med. 55: 351, 1973.PubMedCrossRefGoogle Scholar
  60. 60.
    Luderer, J.R., Hayes, A.H., Dubynsky, O., et al.: Long-term administration of sodium nitroprusside in childhood. J. Pediatr. 91: 490, 1977.PubMedCrossRefGoogle Scholar
  61. 61.
    Novak, D.S., Glassock, R.J., Solomon, D.H., and Maxwell, M.H.: Hypothyroidism following prolonged sodium nitroprusside therapy- Am.J. Med.Sci. 248: 129, 1964.CrossRefGoogle Scholar
  62. 62.
    Page, I.H., Corcoran, A.C., Dustan, H.P., and Koppanyi, T: Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients. Circulation 11: 188, 1955.PubMedGoogle Scholar
  63. 63.
    Danzig, L.E.: Dynamics of thiocyanate dialysis. N. Engl. J. Med. 252: 49, 1955.PubMedCrossRefGoogle Scholar
  64. 64.
    Goldstein, F., and Rieders, F.: Conversion of thiocyanate to cyanide by an erythrocytic enzyme. Am.J.Physiol. 173: 287, 1953.PubMedGoogle Scholar
  65. 65.
    Elberg, A.J., Gorman, H.M., Baker, R., et al.: Prolonged nitroprusside and intermittent hemodialysis as therapy for intractable hypertension. Am. J. Dis. Child 132: 988, 1978.PubMedGoogle Scholar
  66. 66.
    Posner, M.A., Rodkey, F.L., and Tobey, R.E.: Nitroprusside-induced cyanide poisoning: Antidotal effect of hydroxycobaiamin. Anesthesiology 44: 330, 1976.PubMedCrossRefGoogle Scholar
  67. 67.
    Zawada, E.T., Maxwell, M.H., Marks, L.S., Lee, D.B., and Kaufman, J.J: The diagnostic and therapeutic uses of saralasin in renal transplant hypertension. J.Urol. 123: 148, 1980.PubMedGoogle Scholar
  68. 67A.
    Ruley, E.J., Bock, G.H., and Smith, D.: Use of continuous saralasin infusion to control hypertension. J. Pediatr. 101: 1013, 1982.PubMedCrossRefGoogle Scholar
  69. 68.
    Pettinger, W.A.: Minoxidil and the Treatment of Severe Hypertension- N.Engl.J.Med, 303: 922, 1980.Google Scholar
  70. 69.
    Lewy, P.R.: The Management of Resistant Hypertension - The Role of Minoxidil, (eds) Gruskin, A.B., and Norman M.E., In: Developments in Nephrology 3. Pediatric Nephrology. Boston: Martinus Nijhoff, 1981, p. 416.Google Scholar
  71. 70.
    Sinaiko, A.R., O’Dea, R.F., Mirkin, B.L.: Clinical response of hypertensive children to long-term minoxidil therapy. J Cardiovasc. Pharmacol. 2: Suppl: 181, 1980.Google Scholar
  72. 71.
    Sinaiko, A.R., and Mirkin, B.L.: Management of severe childhood hypertension with minoxidil: a controlled study. J-Pediatr-91: 138, 1977.Google Scholar
  73. 72.
    Pennisi, A.F., Bernstein, B.H., Takahashi, M., et al.:Minoxidil therapy in children with severe hypertension, J.Pediatr. 90: 813, 1977.PubMedCrossRefGoogle Scholar
  74. 73.
    Puri, H.C., and Potter, D.E.: Long Term Minoxidil Therapy in Children with Refractory Hypertension- Pediatr - Res. 14: 1009, 1980.Google Scholar
  75. 74.
    Martin, W.B., Spodick, D.H., Zins, G.R.: Pericardial disorders occurring during open-label study of 1,869 severely hypertensive patients treated with minoxidil. J.Cardiovasc.Pharmacol. 1980? 2: Suppl: 227, 1980.Google Scholar
  76. 75.
    O’Malley, K., Velasco, M., Wells, J., McNay, J.L.: Control plasma renin activity and changes in sympathetic tone as determinants of minoxidil-induced increase in plasma renin activity. J.Clin.Invest. 55: 230, 1975.PubMedCrossRefGoogle Scholar
  77. 76.
    Pettinger, W.A., Mitchell, H.C.: Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man. N. Engl. J-Med. 292: 1214, 1975.PubMedCrossRefGoogle Scholar
  78. 77.
    Mitchell, H.C., Pettinger, W.A.: The hypernoradrenergic state in vasodilator drug-treated hypertensive patients; effect of clonidine. J.Cardiovasc.Pharmacol. 2: 1, 1980.PubMedCrossRefGoogle Scholar
  79. 78.
    Makker, S.P., and Moorthy, B.: Rebound hypertension following minoxidil withdrawal- J.Pediatr. 96: 762, 1980.Google Scholar
  80. 79.
    Vidt, D.G., Bravo, E.L., and Fouad, F.M.: Captopril, N. Engl. J.Med. 306: 214, 1982.CrossRefGoogle Scholar
  81. 80.
    Murthy, V.S., Waldron,T.L., Goldberg, M.E.: The mechanism of bradykinin potentiation after inhibition of angiotensin-converting enzyme (SQ 14,225) in conscious rabbits. Circ. Res. 43: Part 2: 1-46–5, 1976.Google Scholar
  82. 81.
    Sullivan, J.M., Ginsburg, B.A., Ratts, T.E., et al.: Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor. Hypertension. 1: 397, 1979.PubMedGoogle Scholar
  83. 82.
    Tarazi, R.C., Bravo, E.L., Fouad, F.M., Omvik, P., Cody, R.J. Jr.: Hemodynamic and volume changes associated with captopril. Hypertension. 2: 576, 1980.PubMedGoogle Scholar
  84. 83.
    Case, D.B., Atlas, S.A., Laragh, J.H., et al.: Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral Converting enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients. Prog.Cardiovasc.Dis. 21: 195, 1978.PubMedCrossRefGoogle Scholar
  85. 83A.
    Textor, S.C., Bravo, E.L., Fouad, F.M., and Tarazi, R.C.: Hyperkalemia in azotemic patients during angiotensin converting enzyme inhibition and aldosterone reduction with captopril. Amer. J. Med. 73: 719, 1982.CrossRefGoogle Scholar
  86. 84.
    Oberfield, S.E., Rapaport, R., Levine, L.S., New, M.I.: Long-Term Treatment of Childhood Hypertension with Captopril- Pediat. Ann. 11: 614, 1982.Google Scholar
  87. 85.
    Waeber, B., Guignard, J.P., Brunner, H.R. et al.:Treatment of severe renal hypertension in a child with an inhibitor of the angiotensin converting enzyme (SQ 14225). Helv-Paediatr.Acta-40(suppl): 10, 1978.Google Scholar
  88. 86.
    Oberfield, S.E., Case, D.B., Levine, L.S., et al.:Brief clinical and laboratory observations: Use of the oral angiotensin I-converting enzyme inhibitor (captopril) in childhood malignant hypertension. J. Pediatr. 95: 641, 1979.PubMedCrossRefGoogle Scholar
  89. 87.
    Bacri, J.L., Dechaux, M., Gingnadoux, M.F., et al.; Short term response and long term management with captopril in severe hypertention (HT) of children. Pediatr.Res. 14: 1009, 1980.CrossRefGoogle Scholar
  90. 88.
    Friedman, A., Chesney, R.W., Ball, D., et al.:Effective use of captopril (angiotensin I-converting enzyme inhibitor) in severe childhood hypertension. J.Pediatr 97: 664, 1980.PubMedCrossRefGoogle Scholar
  91. 89.
    Callis, L., Vila, A., Vilaplana E., and Castello, F.: Effect of Captopril in patients on chronic hemodialysis. Int. J. Pediatr.Neph. 3: 111, 1982.Google Scholar
  92. 90.
    Ploos van Amstel, S.L.B. and Abbad, F.C.B.;Long-term treatment of severe hypertension with Captopril. Int. J. Pediatr.Neph. 3: 107, 1982.Google Scholar
  93. 91.
    Chennavasin, P., Sciwell, R., Brater, D.C. and Liang, W.M.M.: Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kid. Int. 16: 187, 1979.Google Scholar
  94. 92.
    Rubb, W.: Pharmacokinetics and Pharmacodynamics of Lasix. Scot. Med. J. 19: 5, 1974.Google Scholar
  95. 93.
    Dikshit, K., Vyden, J.K., Forrester, J.S., et al.:Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. New.Eng.J.Med. 288: 1087, 1973.PubMedCrossRefGoogle Scholar
  96. 94.
    De Rubertis, F.R., Michells, M.F., Beck, N., Davis, B.B.: Complications of diuretic therapy: Severe alkalosis and syndrome resembling inappropriate secretion of antidiuretic hormone. Metabolism 19: 709, 1970.CrossRefGoogle Scholar
  97. 95.
    Steele, T.H., Rieselbach, R.E.: Renal handling of urate and other organic anions, (eds) Brenner, B.M., and Rector, F.C., In: The Kidney. WB Saunders, 1976, p 460.Google Scholar
  98. 96.
    Schwartz, G.H., David, D.S., Riggio, R.R., et al.:Ototoxicity Induced by Furosemide, New. Engl.’J. Med. 282: 1413, 1970.CrossRefGoogle Scholar
  99. 97.
    Mudge, G.H.: Diuretics and other agents employed in the mobilization of edema fluid, (eds) Gilman, A.G., Goodman, L.S., and Gilman, A. In: The pharmacological basis of therapeutics, 6th edition. McMillan Co., 1980, p. 906.Google Scholar
  100. 98.
    Seedat, Y.K.: High-Dose Furosemide (Lasix) in Renal Insufficiency. S. Arf. Med. J. 46: 1371, 1972.Google Scholar
  101. 99.
    Huang, C.M., Atkinson, A.J., Levin, M., et al.: Pharmacokinetics of furosemide in advanced renal failure. Clin. Pharmacol Ther. 16: 659, 1972.Google Scholar
  102. 100.
    Wollam, G.L., Tarazi, R.C., Bravo, E.L. and Dustanr H.P.: Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Amer. J. Med., 72: 929, 1982.CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Alan B. Gruskin
  • H. Jorge Baluarte
  • Martin S. Polinsky
  • Bruce A. Kaiser
  • Sharon A. Perlman
  • Bruce Z. Morgenstern

There are no affiliations available

Personalised recommendations